MAP2K7 and colorectal cancer: With regard to the gastrointestinal digestive system, colorectal cancer escapes EGFR blockade by downstream signaling activation (RAS-MEK), and combination of EGFR blockade and MEK blockade can prevent resistance both in vitro and in vivo (79).